



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Dated:20.04.2022

To,

The Deputy Manager (Corporate Services)
The Bombay Stock Exchange Limited
1st Floor, Rotunda Bldg
B.S Marg , Fort
Mumbai -400001

Sub: Reconciliation of Share Capital Audit Report as Regulation 76 of SEBI (Depositories and Participant) Regulations, 2018 for the Quarter ended 31st March 2022.

Sir,

We are sending herewith Reconciliation of Share Capital Audit Report as per the Regulation 76 of SEBI (Depositories and Participant) Regulations, 2018 for the Quarter ended on 31st March 2022.

Kindly take note of the same

For Sandu Pharmaceuticals Limited



PRATIKA MHAMBRAY
Company Secretary

Neeta H. Desai

BA, LLB, LLM, FCS
Tel : 02224095104
Mobile: 09821498216
Mobile: 09892288254



279/18 Shantikunj, Road No. 31
Sion East, Mumbai – 400022
E-mail: ndassociates2128@gmail.com
E-mail: ndassociates@rediffmail.com

RECONCILIATION OF SHARE CAPITAL AUDIT

(As per regulation 76 of the SEBI (Depositories and Participants) Regulation, 2018)

1	For Quarter Ended	31st March 2022																
2	ISIN :	INE 751D01014																
3	Face Value :	Rs. 10/- each																
4	Name of the Company	Sandu Pharmaceuticals Limited.																
5	Registered Office Address	Plot No. 25,26,29 & 30, Pilerne Industrial Estate, Marra, Bardez, Goa-403511																
6	Correspondence Address	Plot No. 25,26,29 & 30, Pilerne Industrial Estate, Marra, Bardez, Goa-403511																
7	Telephone & Fax No.	Tel:0832-2407473/74 Fax:0832-2407008																
8	Email address	corp.sec@sandu.in																
9	Names of the Stock Exchanges where the company's securities are listed:	Mumbai Stock Exchange																
		<table border="1"><thead><tr><th>Number of Shares</th><th>% of Total Issued Capital</th></tr></thead><tbody><tr><td>8810664</td><td>-----</td></tr><tr><td>BSE: 7920997</td><td>-----</td></tr><tr><td>31.03.2022</td><td>%</td></tr><tr><td>5339867</td><td>67.41</td></tr><tr><td>1676680</td><td>21.17</td></tr><tr><td>904450</td><td>11.42</td></tr><tr><td>7920997</td><td>100 %</td></tr></tbody></table>	Number of Shares	% of Total Issued Capital	8810664	-----	BSE: 7920997	-----	31.03.2022	%	5339867	67.41	1676680	21.17	904450	11.42	7920997	100 %
Number of Shares	% of Total Issued Capital																	
8810664	-----																	
BSE: 7920997	-----																	
31.03.2022	%																	
5339867	67.41																	
1676680	21.17																	
904450	11.42																	
7920997	100 %																	
10	Issued Capital																	
11	Listed Capital (Exchange wise) (as per company records)																	
12	Held in dematerialized form in NSDL																	
13	Held in dematerialized form in CDSL																	
14	Physical																	
15	Total No. of shares (12+13+14)																	
16	Reasons for difference if any, between (10&11), (10&15), (11&15):	Yes (refer point 25)																
17	Certifying the details of changes in share capital during the quarter under consideration as per Table below:	Yes																

Particulars	No of shares/warrants	Applied / Not applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. appr.pending for SE (Specify Names)
Convertible Warrants	25,79,990	Applied	BSE	Yes	Yes	Received
Equity Shares on Conversion of warrants (1 st & 2 nd)	8,39,997	Applied	BSE	Yes	Yes	Received
	8,89,667	Applied	BSE	Yes	Yes	Received

* Rights, Bonus, Preferential issue, ESOPs/ Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18	Register of Members is updated (Yes / No) If not, updated up to which date			Yes -----
19	Reference of previous quarter with regards to excess Dematerialized shares, if any.			N. A
20	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason for delay:			N. A
21	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :			
	Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
	Confirmed after 21 days	---	---	---
	Pending for more than 21 days	---	---	---
22	Name, Telephone & Fax No. of the Compliance Officer of the Co.	Mrs. Pratika P. Mhambray (Company Secretary & Compliance Officer) Tel:0832-2407473/74 Fax:0832-2407008		
23	Name, Address, Tel. & Fax No., Regn. No. of the Auditor	Neeta H. Desai 279/18, Shantikunj, Sion (E), Road No. 31, Mumbai – 400 022. C. P. No. 4741, Tel: 24095104		
24	Appointment of common agency for share registry work (if yes (name & address))	Link Intime India Private Ltd C-101, 247 Park, L B S Marg, Vikhroli West, Mumbai 400083		
25	Any other detail that the auditor may like to provide	<p>The Company issued 25,79,990 Convertible Warrants and received in principle approval no. DCS/PREF /BA /PRE/ 1120/2020-21 dated 25.03.2021 from BSE. The Said warrants were allotted on 30.03.2021. On 31.03.2021- 8,39,997 equity shares were allotted on 1st tranche of conversion of warrants. The Company has received Trading approval for the same vide letter no. LOD/PREF /TP /VJ/ 13026/ 2021-22 dt. 24.01.2022.</p> <p>On account of 2nd tranche of conversion of warrants 8,89,667 equity shares were allotted on 02.03.2022. Trading permission is awaited form BSE for the same.</p> <p>The above certificate is issued based on the electronic data provided by the Company.</p>		

Note:

The above certificate is issued based on the Register of Members, beneficiary details and other documents furnished by the Company and its Share Transfer Agents M/s. Link Intime India Private Limited and also the explanation given to us.

Place: Mumbai**Date: 19.04.2022****UDIN: F003262D000155062****For ND & Associates**

NEETA
HARKISHAN
DESAI

Neeta H. Desai
Company Secretary
C P No. 4741